Boston Scientific Gains Neuro, Cardiovascular Access Devices Via Acquisition
This article was originally published in The Gray Sheet
Microfabricated guidewires to facilitate interventional cardiology procedures will be developed by Boston Scientific, following the purchase of Precision Vascular Systems, Inc
You may also be interested in...
LipoScience IPO: Sale of 5 mil. shares in $80 mil. initial public offering is postponed Sept. 19. The maker of the NMR LipoProfile cardiovascular disease risk assessment test planned on pricing each share at $14-16 (1"The Gray Sheet" March 11, 2002, p. 18). The IPO, which originally had been targeted to raise $100 mil., was delayed following the stock market downturn the week of Sept. 16. The NMR LipoProfile is more expensive than traditional, standard-of-care cholesterol tests, which may have contributed to investor jitters...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.